Claims for Patent: 9,937,143

Summary for Patent: 9,937,143

Title:	Inhibitors for treating diseases characterized by atrial enlargement or remodeling
Abstract:	The present invention relates to the NEP inhibitor pro-drug N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid ethyl ester, or a pharmaceutically acceptable salt thereof; or the NEP inhibitor N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid, or a pharmaceutically acceptable salt thereof, pro-drug for use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling; a method for treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of the NEP inhibitor or the NEP inhibitor pro-drug, or a pharmaceutically acceptable salt pro-drug thereof, to a subject, e.g. a human subject, in need of such treatment. The present invention further relates to a pharmaceutical composition or a commercial package comprising the NEP inhibitor or the NEP inhibitor pro-drug, or a pharmaceutically acceptable salt thereof, pro-drug for use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling.
Inventor(s):	Christoph Schumacher, Thomas Holbro
Assignee:	Novartis Pharma AG, Novartis Pharmaceuticals Corp
Application Number:	US15/345,941
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,937,143
Patent Claims:	1. A method for the treatment of heart failure with preserved ejection fraction (HF-PEF) in a human patient comprising administration of a therapeutically effective amount of the NEP inhibitor pro-drug N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid ethyl ester to the patient in need of such treatment, wherein the NEP inhibitor pro-drug is administered together with the Angiotensin Receptor Blocker valsartan in a 1:1 molar ratio in the form of LCZ696 as trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate-(S)-3′-methyl-Z-(pentanoyl{2″-(tetrazol-5-ylate)biphenyl-4′-ylmethyl}amino)butyrate]hemipentahydrate. 2. The method according to claim 1, wherein the method is for the treatment of atrial fibrillation. 3. The method according to claim 1, wherein the method is for the treatment of patients with no history of atrial fibrillation. 4. The method according to claim 1, wherein the method is for the use of reducing the level of plasma NT-proBNP. 5. The method according to claim 1, wherein the administration of the NEP inhibitor pro-drug or NEP inhibitor leads to a sustained reduction in plasma NT-proBNP concentration. 6. The method according to claim 1, wherein the method is for the improvement, stabilization or delayed worsening in NYHA classification of patients suffering from heart failure. 7. The method according to claim 1 wherein LCZ696 is administered twice daily at a dose of 50 mg, 100 mg, 200 mg or 400 mg. 8. The method according to claim 1, wherein the treatment is characterized by the reduction of the left atrial volume, the left atrial volume index (LAVI) and/or the left atrial dimension.